
Amorphous PTX
enhances coating durability and prompt drug availability for immediate action and short-term residency7

Crystalline PTX
forms drug depots that dissolve into tissue slowly for sustained residency7
0.014" DCB is not approved for distribution, sale or use in the USA.
Availability of this product may vary by country.
Stellarex EnduraCoat technology achieves uniform and acute drug transfer and sustained tissue residency at therapeutic levels through 28 days, minimizing restenosis.
Stellarex demonstrates low particulate loss,9 which may reduce the risk of downstream embolization and, at the same time, enable a low therapeutic drug dose.
A comparative study of Stellarex versus PTA in a swine model of in-stent restenosis demonstrates Stellarex DCB’s efficacy at 28 days, indicated by minimal luminal loss and consistent treatment effect.9